<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">neurosurgery</journal-id><journal-title-group><journal-title xml:lang="ru">Нейрохирургия</journal-title><trans-title-group xml:lang="en"><trans-title>Russian journal of neurosurgery</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1683-3295</issn><issn pub-type="epub">2587-7569</issn><publisher><publisher-name>Издательский дом "МедИНК"</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.17650/1683-3295-2022-24-2-17-24</article-id><article-id custom-type="elpub" pub-id-type="custom">neurosurgery-1193</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНАЯ РАБОТА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL REPORT</subject></subj-group></article-categories><title-group><article-title>Оценка результатов нейрохирургической операции в комплексном лечении солитарных церебральных метастазов</article-title><trans-title-group xml:lang="en"><trans-title>Surgical treatment of solitare brain metastases</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2615-269X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Станишевский</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Stanishevskiy</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Артём Вадимович Станишевский</p><p>105094 Москва, Госпитальная пл., 3</p></bio><bio xml:lang="en"><p>Artem Vadimovich Stanishevskiy</p><p>3 Gospitalnaya Sq., Moscow 105094</p></bio><email xlink:type="simple">a-stan@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-2953-9902</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Гизатуллин</surname><given-names>Ш. Х.</given-names></name><name name-style="western" xml:lang="en"><surname>Gizatullin</surname><given-names>Sh. Kh.</given-names></name></name-alternatives><bio xml:lang="ru"><p>105094, Москва, Госпитальная пл., 3</p></bio><bio xml:lang="en"><p>3 Gospitalnaya Sq., Moscow 105094</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3023-0515</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Смолин</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Smolin</surname><given-names>A. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>105094, Москва, Госпитальная пл., 3</p></bio><bio xml:lang="en"><p>3 Gospitalnaya Sq., Moscow 105094</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-8396-1936</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Крюков</surname><given-names>Е. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Kryukov</surname><given-names>E. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>105094, Москва, Госпитальная пл., 3</p></bio><bio xml:lang="en"><p>3 Gospitalnaya Sq., Moscow 105094</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБУ «Главный военный клинический госпиталь им. акад. Н. Н. Бурденко» Минобороны России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Main Military Clinical Hospital named after Academician N. N. Burdenko, Ministry of Defense of Russia</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2022</year></pub-date><pub-date pub-type="epub"><day>10</day><month>06</month><year>2022</year></pub-date><volume>24</volume><issue>2</issue><fpage>17</fpage><lpage>24</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Станишевский А.В., Гизатуллин Ш.Х., Смолин А.В., Крюков Е.В., 2022</copyright-statement><copyright-year>2022</copyright-year><copyright-holder xml:lang="ru">Станишевский А.В., Гизатуллин Ш.Х., Смолин А.В., Крюков Е.В.</copyright-holder><copyright-holder xml:lang="en">Stanishevskiy A.V., Gizatullin S.K., Smolin A.V., Kryukov E.V.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.therjn.com/jour/article/view/1193">https://www.therjn.com/jour/article/view/1193</self-uri><abstract><sec><title>Введение</title><p>Введение. Церебральные метастазы встречаются у 10–30 % пациентов с различными формами рака. Несмотря на успехи, достигнутые в лечении онкологических заболеваний внечерепных локализаций в последнее десятилетие, тенденция к увеличению выживаемости и длительности безрецидивного периода у пациентов с церебральными метастазами не прослеживается.</p><p>Цель исследования – анализ опыта комплексного лечения церебральных метастазов в многопрофильном стационаре на основе обзора литературных данных о современных тенденциях.</p></sec><sec><title>Материалы и методы</title><p>Материалы и методы. Проведен ретроспективный анализ медицинской документации пациентов с церебральными метастазами: оценивались частота их возникновения в зависимости от положения первичной опухоли, объем, локализация, ранние осложнения, подсчитаны медиана общей выживаемости и длительность стационарного лечения. Критерии исключения: множественное метастатическое поражение головного мозга, противопоказания к хирургическому лечению церебральных метастазов, высокочувствительные к химио- и лучевой терапии опухоли (лейкоз, лимфома, герминогенные опухоли). Радикальность удаления метастазов оценивалась при помощи послеоперационных КТ и МРТ с внутривенным контрастированием и протоколов операций, катамнез – анкетирования родственников. Статистическая обработка данных велась на основе пакета программ IBM SPSS Statistics 23.</p></sec><sec><title>Результаты</title><p>Результаты. Критериям включения соответствовали 52 пациента, средний возраст на момент операции – 60 лет. Наиболее частые (в порядке убывания) источники церебральных метастазов: меланома, рак легкого, почки, молочной железы, прямой кишки, простаты, яичника, матки. Наиболее распространенные (в порядке убывания) варианты локализации метастазов: теменная, лобная доли, полушария мозжечка, затылочная, височная доли, желудочковая система и оболочки головного мозга. В 46 % случаев метастазы локализовались в функционально значимых областях головного мозга. Медиана объема метастазов – 11 см3. Гипертензионно-дислокационный синдром отмечен у 65,4 % пациентов. Медианное значение индекса Карновского при поступлении – 73,8 балла. В 84,6 % случаев достигнуто тотальное удаление метастаза, в 7,7 % – субтотальное. Катамнез доступен для 44 пациентов, на момент проведения исследования у 20 из них наступил летальный исход. Факторы, влияющие на прогноз при церебральных метастазах: морфология и объем метастаза, тотальность удаления, состояние больного при поступлении (индекс Карновского), наличие ранних осложнений.</p></sec><sec><title>Заключение</title><p>Заключение. В большинстве случаев пациенты с церебральными метастазами при поступлении в стационар находятся в удовлетворительном состоянии. Метастазирование в головной мозг более характерно для меланомы и рака легкого, эти опухоли характеризуются худшим прогнозом. Большинство метастазов локализуются супратенториально и часто вызывают развитие гипертензионно-дислокационного синдрома. Локализация метастаза, срок от момента его выявления до хирургического лечения, отношение к функционально значимым зонам, а также факт удаления первичной опухоли не влияют на выживаемость.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Background</title><p>Background. Brain metastasis occurs in 10–30 % of patients with different malignances. Despite of successes, achieved in the treatment of extracranial malignances in last decade, tendency to increase of the survival and duration of the disease-free period in patients with brain metastasis is absent. Several treatment modalities: chemotherapy, radiation, immune and target therapy, stereotactic radiosurgery, different types of surgical procedures, however, an optimal combination of these methods remain unclear.</p></sec><sec><title>The aim of the study</title><p>The aim of the study: to summarize experience of complex treatment of patients with brain metastases in hospital with opportunity of both surgical removal, chemo- and radiotherapy and review literature on the topic.</p></sec><sec><title>Materials and methods</title><p>Materials and methods. The retrospective analysis of medical data of patients with brain metastases performed with assessment of most frequent sources of metastases, there value, localization, median survival duration from metastasis revealing due to different types of therapy, main period of recurrences and hospital state duration, early and late complications. Inclusion criteria were: patients with surgical treatment of brain metastases, availability of medical data. Exclusion criteria were: multiple brain metastases, contraindications for surgical treatment, sensitive to chemo- and radiation therapy malignances (leukoses, lymphoma, germinative tumors etc.). The assessment of degree of metastasis resection was made by postop CT and MRI with intravenous enhancement or by operation records. Intraoperative florescence was used for evaluation of tumor borders. In case of localization of metastasis in sensory or motor zones intraoperative electrophysiological monitoring acquired. Few operations for metastasis localized in speech zones were made with «asleep–awake–asleep» method. Follow-up assessed by questioning of patients and their relatives. Statistical analyzes performed in IBM SPSS Statistics 23.</p></sec><sec><title>Results</title><p>Results. 52 patients meet criteria and were included to the study. Male to female ratio was 1 : 1, main age – 60 years.  The most common sources of brain metastases were (in decreasing order) melanoma, lung cancer, kidney cancer, breast cancer, rectal cancer, prostate cancer, ovarian cancer and uterus cancer. Two patients had 2 brain metastases at the time of assessment, other 50 – single. Most common localizations of brain metastases (in decreasing order) were: parietal lobe, frontal lobe, cerebellum hemispheres, occipital lobe, temporal lobe, ventricular system and brain meninges. In 46 % of cases metastases involves significant functional areas of brain. Median value of metastasis was 11 cm3; midline dislocation appeared in 65,4 % of cases; 6 patients have hemorrhage in the tumor, 2 – seizures, 2 – occlusive hydrocephalus. Main Karnofsky performance index – 73,8. Total resection performed in 84,6, subtotal resection – in 7,7 % of cases gross. Intraoperative fluorescence used in 73 %. In 10 cases metastasis localized in motor and sensory zones, all these cases were treat with intraoperative neurophysiological monitoring. Postoperative hemiparesis noticed in 1 patient; 3 surgeries performed with awake; no aphasias mentioned. Follow-up was assessed in 44 patients, 20 of them were dead at the time of the study. An assessment of dependence of overall survival median on primary tumor morphology performed. Prognostic factors of brain metastases: its morphology and value, extent of resection, Karnofsky status and early complications.</p></sec><sec><title>Conclusions</title><p>Conclusions. Most patients with brain metastasis are in satisfactory condition. Most frequent tumors which form brain metastasis: melanoma and lung cancer, they are characterized by poorer prognosis. Most metastasis are supratentorial, intracranial hypertension is obvious. Metastasis localization, time from its evaluation to surgery, significant functional areas involvement and primary tumor resection aren’t fluent on survival.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>метастаз</kwd><kwd>химиотерапия</kwd><kwd>лучевая терапия</kwd><kwd>опухоль</kwd><kwd>головной мозг</kwd><kwd>меланома</kwd><kwd>рак</kwd><kwd>аденокарцинома</kwd></kwd-group><kwd-group xml:lang="en"><kwd>metastasis</kwd><kwd>chemotherapy</kwd><kwd>radiation therapy</kwd><kwd>tumor</kwd><kwd>brain</kwd><kwd>melanoma</kwd><kwd>cancer</kwd><kwd>adenocarcinoma</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">DeAngelis L.M. Intracranial Metastases. In: Neurologic Complications of Cancer. Neuro Oncol 2009;11(1):96–7. DOI: 10.1215/15228517-2008-118.</mixed-citation><mixed-citation xml:lang="en">DeAngelis L.M. Intracranial Metastases. In: Neurologic Complications of Cancer. Neuro Oncol 2009;11(1):96–7. DOI: 10.1215/15228517-2008-118.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Patchell R.A., Tibbs P.A., Walsh J.W. et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990;322(8):494–500. DOI: 10.1056/NEJM199002223220802.</mixed-citation><mixed-citation xml:lang="en">Patchell R.A., Tibbs P.A., Walsh J.W. et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990;322(8):494–500. DOI: 10.1056/NEJM199002223220802.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Голанов А.В., Банов С.М. и др. Лечение пациентов с метастатическим поражением головного мозга. Журнал «Вопросы нейрохирургии» им. Н.Н. Бурденко 2016;80(4):89–100.</mixed-citation><mixed-citation xml:lang="en">Golanov A.V., Banov S.M. et al. Treatment of patients with brain metastases. Zhurnal Voprosy Neirokhirurgii imeni N.N. Burdenko = Burdenko’s Journal of Neurosurgery 2016;80(4):89–101. (In Russ., in Eng.). DOI: 10.17116/neiro201680489-100.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Древаль О.Н. Нейрохирургия: Руководство в 2 т. М.: ГЭОТАР-Медиа, 2013. 864 р.</mixed-citation><mixed-citation xml:lang="en">Dreval O.N. Neurosurgery: A guide in 2 vol. Moscow: GEOTARMedia, 2013. 864 p. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">O’Connell K., Romo C.G., Grossman S.A. Brain metastases as a first site of recurrence in patients on chemotherapy with controlled systemic cancers: An increasingly urgent clinical scenario. J Clin Oncol 2019;37(15_suppl):e13590. DOI: 10.1200/jco.2019.37.15_suppl.e13590.</mixed-citation><mixed-citation xml:lang="en">O’Connell K., Romo C.G., Grossman S.A. Brain metastases as a first site of recurrence in patients on chemotherapy with controlled systemic cancers: An increasingly urgent clinical scenario. J Clin Oncol 2019;37(15_suppl):e13590. DOI: 10.1200/jco.2019.37.15_suppl.e13590.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Гайдар Б.В., Парфенов В.Е., Щербук Ю.А. и др. Лечебная тактика при раке почки с метастатическим поражением центральной нервной системы. Практическая онкология 2005;6(3):172–7.</mixed-citation><mixed-citation xml:lang="en">Gaidar B.V., Parfenov V.E., Shcherbuk Yu.A. et al. Тreatment strategy for kidney cancer with CNS metastasis. Prakticheskaya onkologiya = Practical oncology 2005;6(3):172–7. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">O’Halloran P.J., Gutierrez E., Kalyvas A. et al. Brain metastases: A modern multidisciplinary approach. Can J Neurol Sci 2021;48(2):189–97. DOI: 10.1017/cjn.2020.224.</mixed-citation><mixed-citation xml:lang="en">O’Halloran P.J., Gutierrez E., Kalyvas A. et al. Brain metastases: A modern multidisciplinary approach. Can J Neurol Sci 2021;48(2):189–97. DOI: 10.1017/cjn.2020.224.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Ротин Д.Л. Клинико-морфологические и молекулярно-биологические аспекты развития метастазов в головной мозг. Журнал «Вопросы нейрохирургии» имени Н.Н. Бурденко 2012;76(2):70–6.</mixed-citation><mixed-citation xml:lang="en">Rotin D.L. Clinico-morphological and molecular-biological aspects of cerebral metastases development. Zhurnal Voprosy Neirokhirurgii imeni N.N. Burdenko = Burdenko’s Journal of Neurosurgery 2012;76(2):70–6. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Vogelbaum M.A., Suh J.H. Resectable brain metastases. J Clin Oncol 2006;24(8):1289–94. DOI: 10.1200/JCO.2005.04.6235.</mixed-citation><mixed-citation xml:lang="en">Vogelbaum M.A., Suh J.H. Resectable brain metastases. J Clin Oncol 2006;24(8):1289–94. DOI: 10.1200/JCO.2005.04.6235.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">de Boer A.G., Gaillard P.J. Drug Targeting to the Brain. Annu Rev Pharmacol Toxicol 2007;47:323–55. DOI: 10.1146/annurev.pharmtox.47.120505.105237.</mixed-citation><mixed-citation xml:lang="en">de Boer A.G., Gaillard P.J. Drug Targeting to the Brain. Annu Rev Pharmacol Toxicol 2007;47:323–55. DOI: 10.1146/annurev.pharmtox.47.120505.105237.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Pardridge W.M. The blood-brain barrier: bottleneck in brain drug development. NeuroRX 2005;2(1):3–14. DOI: 10.1602/neurorx.2.1.3.</mixed-citation><mixed-citation xml:lang="en">Pardridge W.M. The blood-brain barrier: bottleneck in brain drug development. NeuroRX 2005;2(1):3–14. DOI: 10.1602/neurorx.2.1.3.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Neuwelt E.A., Maravilla K.R., Frenkel E.P. et al. Osmotic bloodbrain barrier disruption. Computerized tomographic monitoring of chemotherapeutic agent delivery. J Clin Invest 1979;64(2):684–8. DOI: 10.1172/JCI109509.</mixed-citation><mixed-citation xml:lang="en">Neuwelt E.A., Maravilla K.R., Frenkel E.P. et al. Osmotic bloodbrain barrier disruption. Computerized tomographic monitoring of chemotherapeutic agent delivery. J Clin Invest 1979;64(2):684–8. DOI: 10.1172/JCI109509.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">van Tellingen O., Yetkin-Arik B., de Gooijer M.C. Overcoming the bloodbrain tumor barrier for effective glioblastoma treatment. Drug Resist Updat 2015;(19):1–12. DOI: 10.1016/j.drup.2015.02.002.</mixed-citation><mixed-citation xml:lang="en">van Tellingen O., Yetkin-Arik B., de Gooijer M.C. Overcoming the bloodbrain tumor barrier for effective glioblastoma treatment. Drug Resist Updat 2015;(19):1–12. DOI: 10.1016/j.drup.2015.02.002.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Zawadzki M., Walecki J., Kostkiewicz B. et al. Republished: Real-time MRI guidance for intra-arterial drug delivery in a patient with a brain tumor: technical note. J Neurointerv Surg 2019;11(8):e3. DOI: 10.1136/neurintsurg-2018-014469.rep.</mixed-citation><mixed-citation xml:lang="en">Zawadzki M., Walecki J., Kostkiewicz B. et al. Republished: Real-time MRI guidance for intra-arterial drug delivery in a patient with a brain tumor: technical note. J Neurointerv Surg 2019;11(8):e3. DOI: 10.1136/neurintsurg-2018-014469.rep.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Hendriks L.E., Henon C., Auclin E. et al. Outcome of patients with non-small cell lung cancer and brain metastases treated with checkpoint inhibitors. J Thorac Oncol 2019;14(7):1244–54. DOI: 10.1016/j.jtho.2019.02.009.</mixed-citation><mixed-citation xml:lang="en">Hendriks L.E., Henon C., Auclin E. et al. Outcome of patients with non-small cell lung cancer and brain metastases treated with checkpoint inhibitors. J Thorac Oncol 2019;14(7):1244–54. DOI: 10.1016/j.jtho.2019.02.009.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Hardesty D.A., Nakaji P. The current and future treatment of brain metastases. 2016;3:30. DOI: 10.3389/fsurg.2016.00030.</mixed-citation><mixed-citation xml:lang="en">Hardesty D.A., Nakaji P. The current and future treatment of brain metastases. 2016;3:30. DOI: 10.3389/fsurg.2016.00030.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Банов С.М., Смолин А.В., Насхлеташвили Д.Р. и др. Таргетная терапия в сочетании с радиохирургией у пациентов с метастазами в головной мозг. Злокачественные опухоли 2016;4S1(21):74–80.</mixed-citation><mixed-citation xml:lang="en">Banov S.M., Smolin A.V., Naskhletashvili D.R. et al. Target therapy with radiosurgery in patients with cerebral metastasis. Zlokachestvennye opukholi = Malignant tumours 2016;4S1(21):74–80. (In Russ.). DOI: 10.18027/2224-5057-2016-4s1-74-80.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Токарев А.С., Евдокимова О.Л., Рак В.А., Викторова О.А. Радиохирургическое лечение метастазов рака яичников в головной мозг. Лучевая диагностика и терапия 2020;11(3):104–10.</mixed-citation><mixed-citation xml:lang="en">Tokarev A.S., Evdokimova O.L., Rak V.A., Viktorova O.A. Radiosurgical treatment for brain metastases of ovarian cancer. Luchevaya diagnostika i terapiya = Diagnostic radiology and radiotherapy 2020;11(3):104–10. (In Russ.). DOI: 10.22328/2079-5343-2020-11-3-104-110.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Brown P.D., Gondi V., Pugh S. et al. Hippocampal avoidance during wholebrain radiotherapy plus memantine for patients with brain metastases: Phase III Trial NRG Oncology CC001. J Clin Oncol 2020;38(10):1019–29. DOI: 10.1200/JCO.19.02767.</mixed-citation><mixed-citation xml:lang="en">Brown P.D., Gondi V., Pugh S. et al. Hippocampal avoidance during wholebrain radiotherapy plus memantine for patients with brain metastases: Phase III Trial NRG Oncology CC001. J Clin Oncol 2020;38(10):1019–29. DOI: 10.1200/JCO.19.02767.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Ветлова Е.Р., Голанов А.В., Банов С.М. Современная стратегия комбинации хирургического и лучевого лечения у пациентов с метастазами в головном мозге. Журнал «Вопросы нейрохирургии» им. Н.Н. Бурденко 2017;81(6): 108–15.</mixed-citation><mixed-citation xml:lang="en">Vetlova E.R., Golanov A.V., Banov S.M. A modern strategy of combined surgical and radiation treatment in patients with brain metastases. Zhurnal Voprosy Neirokhirurgii im. N.N. Burdenko =Burdenko’s Journal of Neurosurgery 2017;81(6):108–15. (In Russ., in Eng.). DOI 10.17116/neiro2017816108-115.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Никитин Д.И., Зубаткина И.С., Иванов П.И. Радиохирургическое лечение метастазов почечно-клеточного рака на аппарате «Гамма-нож». Русский медицинский журнал 2017;(16):1164–8.</mixed-citation><mixed-citation xml:lang="en">Nikitin D.I., Zubatkina I.S., Ivanov P.I. Radiosurgical treatment of metastases of renal cell carcinoma on the apparatus “Gamma-knife”. Russkiy meditsinskiy zhurnal = Russian medical journal 2017;(16):1164–8. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Delishaj D., Ursino S., Pasqualetti F. et al. Bevacizumab for the treatment of radiation-induced cerebral necrosis: A systematic review of the literature. J Clin Med Res 2017;9(4):273–80. DOI: 10.14740/jocmr2936e.</mixed-citation><mixed-citation xml:lang="en">Delishaj D., Ursino S., Pasqualetti F. et al. Bevacizumab for the treatment of radiation-induced cerebral necrosis: A systematic review of the literature. J Clin Med Res 2017;9(4):273–80. DOI: 10.14740/jocmr2936e.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Co J., de Moraes M.V., Katznelson R. et al. Hyperbaric oxygen for radiation necrosis of the brain. Can J Neurol Sci 2020;n47(1):92–9. DOI:10.1017/cjn.2019.290.</mixed-citation><mixed-citation xml:lang="en">Co J., de Moraes M.V., Katznelson R. et al. Hyperbaric oxygen for radiation necrosis of the brain. Can J Neurol Sci 2020;n47(1):92–9. DOI:10.1017/cjn.2019.290.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Jethwa P.R., Barrese J.C., Gowda A. et al. Magnetic resonance thermometry-guided laser-induced thermal therapy for intracranial neoplasms: initial experience. Neurosurgery 2012;71(1 Suppl):133–44;144–5. DOI: 10.1227/NEU.0b013e31826101d4.</mixed-citation><mixed-citation xml:lang="en">Jethwa P.R., Barrese J.C., Gowda A. et al. Magnetic resonance thermometry-guided laser-induced thermal therapy for intracranial neoplasms: initial experience. Neurosurgery 2012;71(1 Suppl):133–44;144–5. DOI: 10.1227/NEU.0b013e31826101d4.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Rahmathulla G., Recinos P.F., Kamian K. et al. MRI-guided laser interstitial thermal therapy in neuro-oncology: A review of its current clinical applications. Oncology 2014;87(2):67–82. DOI: 10.1159/000362817.</mixed-citation><mixed-citation xml:lang="en">Rahmathulla G., Recinos P.F., Kamian K. et al. MRI-guided laser interstitial thermal therapy in neuro-oncology: A review of its current clinical applications. Oncology 2014;87(2):67–82. DOI: 10.1159/000362817.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Mirza F.A., Mitha R., Shamim M.S. Current role of laser interstitial thermal therapy in the treatment of intracranial tumors. Asian J Neurosurg 2020;15(4):800–8. DOI: 10.4103/ajns.AJNS_185_20.</mixed-citation><mixed-citation xml:lang="en">Mirza F.A., Mitha R., Shamim M.S. Current role of laser interstitial thermal therapy in the treatment of intracranial tumors. Asian J Neurosurg 2020;15(4):800–8. DOI: 10.4103/ajns.AJNS_185_20.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
